85185-33-7

Upstream product

• 61871-67-8 3-(3,4-Dimethoxyphenyl)propanal 
• 1449-46-3 benzyltriphenylphosphonium bromide 
• 3945-85-5 1-bromo-3-(3,4-dimethoxyphenyl)propane 
• 3929-47-3 3-(3,4-dimethoxyphenyl)-1-propanol 

Downstream Products

• 85185-44-0 ((1R,2R)-6,7-Dimethoxy-1-phenyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-methanol 
• 85185-44-0 ((1R,2S)-6,7-Dimethoxy-1-phenyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-methanol 
• 1191292-65-5 (1S,2S)-N-(6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-4-nitro-benzenesulfonamide 
• 946412-82-4 1,2-dimethoxy-4-(4-phenylbutyl)benzene 
• 1315338-44-3 (1R,2R)-N-(6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-4-nitro-benzenesulfonamide 
• 406174-91-2 (1R,2R)-6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylamine 
• 137417-08-4 (+)-Dihydrexidine hydrochloride 
• 1315338-50-1 (6aR,12bS)-10,11-dimethoxy-6-(4-nitrobenzenesulfonyl)-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine 
• 1315338-46-5 (1R,2R)-N-(6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-methoxymethyl-4-nitro-benzenesulfonamide 
• 1315338-52-3 C₂₈H₃₂N₂O₈S 

Relevant academic research and scientific papers

Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors

Drug efflux pumps confer multidrug resistance to dangerous bacterial pathogens which makes these proteins promising drug targets. Herein, we present initial chemical optimization and structure-activity relationship (SAR) data around a previously described efflux pump inhibitor, nordihydroguaretic acid (NDGA). Four series of novel NDGA analogues that target Escherichia coli AcrB were designed, synthesized and evaluated for their ability to potentiate the activity of antibiotics, to inhibit AcrB-mediated substrate efflux and reduce off-target activity. Nine novel structures were identified that increased the efficacy of a panel of antibiotics, inhibited drug efflux and reduced permeabilization of the bacterial outer and inner membranes. Among them, WA7, WB11 and WD6 possessing broad-spectrum antimicrobial sensitization activity were identified as NDGA analogues with favorable properties as potential AcrB inhibitors, demonstrating moderate improvement in potency as compared to NDGA. In particular, WD6 was the most broadly active analogue improving the activity of all four classes of antibacterials tested.

Asymmetric synthesis of the dopamine D1 agonist, dihydrexidine

A concise asymmetric synthesis of first, high affinity domaine D1 full agonist, dihydrexidine has been accomplished via catalytic enantioselective aziridination and subsequent one-pot Friedel-Crafts cyclization of an in situ generated tethered aziridine w

A catalytic and enantioselective synthesis of trans-2-amino-1-aryltetralins

The bis-oxazoline-copper complex-catalyzed aziridination of alkenes followed by an intramolecular Friedel-Crafts alkylation of the tethered and in situ generated aziridine provides a one-pot, general and efficient method for the synthesis of trans-2-amino